Trial Profile
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Pefcalcitol (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cutanea Life Sciences; Maruho
- 13 Apr 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Jan 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 29 Jan 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.